{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:30:47Z","timestamp":1786408247649,"version":"build-2736575974"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"DOI":"10.1186\/s12913-026-14847-x","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T10:24:04Z","timestamp":1780568644000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Empirical estimate for the indirect healthcare costs of sickle cell disease from a retrospective cohort study in England between 2007 and 2019"],"prefix":"10.1186","volume":"26","author":[{"given":"Caoimhe T.","family":"Rice","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Besser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine L.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmine","family":"Colavecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer A.","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremy P.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna Tedesco","family":"Barcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"14847_CR1","doi-asserted-by":"publisher","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","volume":"4","author":"GJ Kato","year":"2018","unstructured":"Kato GJ, Piel FB, Reid CD, Gaston MH, Ohene-Frempong K, Krishnamurti L, et al. Sickle cell disease. Nat Rev Dis Primers. 2018;4:18010. https:\/\/doi.org\/10.1038\/nrdp.2018.10.","journal-title":"Nat Rev Dis Primers"},{"issue":"8","key":"14847_CR2","doi-asserted-by":"publisher","first-page":"e633","DOI":"10.1016\/S2352-3026(23)00096-0","volume":"10","author":"FB Piel","year":"2023","unstructured":"Piel FB, Rees DC, DeBaun MR, Nnodu O, Ranque B, Thompson AA, et al. Defining global strategies to improve outcomes in sickle cell disease: A Lancet Haematology Commission. Lancet Haematol. 2023;10(8):e633\u201386. https:\/\/doi.org\/10.1016\/S2352-3026(23)00096-0.","journal-title":"Lancet Haematol"},{"issue":"9757","key":"14847_CR3","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1016\/s0140-6736(10)61029-x","volume":"376","author":"DC Rees","year":"2010","unstructured":"Rees DC, Williams TN, Gladwin MT. Sickle-cell disease. Lancet. 2010;376(9757):2018\u201331. https:\/\/doi.org\/10.1016\/s0140-6736(10)61029-x.","journal-title":"Lancet"},{"issue":"5","key":"14847_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1001\/jama.2014.11011","volume":"6","author":"JB Herrick","year":"1910","unstructured":"Herrick JB. Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia. Arch Intern Med (Chic). 1910;6(5):517\u201321. https:\/\/doi.org\/10.1001\/jama.2014.11011.","journal-title":"Arch Intern Med (Chic)"},{"issue":"2","key":"14847_CR5","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/ejh.14211","volume":"113","author":"M de Montalembert","year":"2024","unstructured":"de Montalembert M, Anderson A, Costa FF, Inusa BPD, Jastaniah W, Kunz JB, et al. Sickle Cell Health Awareness, Perspectives, and Experiences (SHAPE) survey: Perspectives of adolescent and adult patients, caregivers, and healthcare professionals on the burden of sickle cell disease. Eur J Haematol. 2024;113(2):172\u201382. https:\/\/doi.org\/10.1111\/ejh.14211.","journal-title":"Eur J Haematol"},{"issue":"4","key":"14847_CR6","doi-asserted-by":"publisher","first-page":"e0297469","DOI":"10.1371\/journal.pone.0297469","volume":"19","author":"A Singh","year":"2024","unstructured":"Singh A, Brousseau DC, Dasgupta M, Shet AS, Field JJ, Brandow AM. Acute care utilization among individuals with sickle cell disease and related cardiopulmonary and renal complications. PLoS ONE. 2024;19(4):e0297469. https:\/\/doi.org\/10.1371\/journal.pone.0297469.","journal-title":"PLoS ONE"},{"issue":"9","key":"14847_CR7","doi-asserted-by":"publisher","first-page":"e5769","DOI":"10.1002\/pds.5769","volume":"33","author":"PN Ericksen","year":"2024","unstructured":"Ericksen PN, Dabbous F, Ghosh R, Shah S, Sun X, Meier ER, Colavecchia C. Standardization of coding definitions for sickle cell disease complications: A systematic literature review. Pharmacoepidemiol Drug Saf. 2024;33(9):e5769. https:\/\/doi.org\/10.1002\/pds.5769.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"14847_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1182\/asheducation-2017.1.435","volume":"2017","author":"E Vichinsky","year":"2017","unstructured":"Vichinsky E. Chronic organ failure in adult sickle cell disease. Hematol Am Soc Hematol Educ Program. 2017;2017(1):435\u20139. https:\/\/doi.org\/10.1182\/asheducation-2017.1.435.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"2","key":"14847_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1111\/bjh.14346","volume":"176","author":"BA Davis","year":"2017","unstructured":"Davis BA, Allard S, Qureshi A, Porter JB, Pancham S, Win N, et al. Guidelines on red cell transfusion in sickle cell disease. Part I: principles and laboratory aspects. Br J Haematol. 2017;176(2):179\u201391. https:\/\/doi.org\/10.1111\/bjh.14346.","journal-title":"Br J Haematol"},{"issue":"8","key":"14847_CR10","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1401731","volume":"371","author":"MR DeBaun","year":"2014","unstructured":"DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, et al. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med. 2014;371(8):699\u2013710. https:\/\/doi.org\/10.1056\/NEJMoa1401731.","journal-title":"N Engl J Med"},{"issue":"9870","key":"14847_CR11","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S0140-6736(12)61726-7","volume":"381","author":"J Howard","year":"2013","unstructured":"Howard J, Malfroy M, Llewelyn C, Choo L, Hodge R, Johnson T, et al. The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: A randomised, controlled, multicentre clinical trial. Lancet. 2013;381(9870):930\u20138. https:\/\/doi.org\/10.1016\/S0140-6736(12)61726-7.","journal-title":"Lancet"},{"issue":"12, Supplement","key":"14847_CR12","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.jval.2024.10.350","volume":"27","author":"GT Barcelos","year":"2024","unstructured":"Barcelos GT, Rice C, Carvalho SJ, Wirz R, Filonenko A, Jiang L, Davidson J. EE66 Estimated Cost of Automated Red Cell Exchange Transfusion (ARCET) for Treatment of Sickle Cell Disease (SCD) in the English NHS: Data From a Longitudinal Real-World Cohort. Value Health. 2024;27(12, Supplement):S66. https:\/\/doi.org\/10.1016\/j.jval.2024.10.350.","journal-title":"Value Health"},{"issue":"5","key":"14847_CR13","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1182\/bloodadvances.2023012002","volume":"8","author":"RD Gordon","year":"2024","unstructured":"Gordon RD, Welkie RL, Quaye N, Hankins JS, Kassim AA, Thompson AA, et al. Burden of employment loss and absenteeism in adults and caregivers of children with sickle cell disease. Blood Adv. 2024;8(5):1143\u201350. https:\/\/doi.org\/10.1182\/bloodadvances.2023012002.","journal-title":"Blood Adv"},{"issue":"8","key":"14847_CR14","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.jval.2021.02.014","volume":"24","author":"D Holdford","year":"2021","unstructured":"Holdford D, Vendetti N, Sop DM, Johnson S, Smith WR. Indirect economic burden of sickle cell disease. Value Health. 2021;24(8):1095\u2013101. https:\/\/doi.org\/10.1016\/j.jval.2021.02.014.","journal-title":"Value Health"},{"issue":"6","key":"14847_CR15","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1007\/s11136-019-02412-5","volume":"29","author":"AA Rizio","year":"2020","unstructured":"Rizio AA, Bhor M, Lin X, McCausland KL, White MK, Paulose J, et al. The relationship between frequency and severity of vaso-occlusive crises and health-related quality of life and work productivity in adults with sickle cell disease. Qual Life Res. 2020;29(6):1533\u201347. https:\/\/doi.org\/10.1007\/s11136-019-02412-5.","journal-title":"Qual Life Res"},{"key":"14847_CR16","doi-asserted-by":"publisher","first-page":"4930","DOI":"10.1182\/blood-2018-99-120136","volume":"132","author":"M Idowu","year":"2018","unstructured":"Idowu M, Chung TH, Yu K. Association between employment status and hospitalization of patients with sickle cell disease: A retrospective, observational pilot study. Blood. 2018;132:4930. https:\/\/doi.org\/10.1182\/blood-2018-99-120136.","journal-title":"Blood"},{"issue":"21","key":"14847_CR17","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1182\/blood.V122.21.2244.2244","volume":"122","author":"M Idowu","year":"2013","unstructured":"Idowu M, Fawibe O, Rowan P, Juneja HS, Brown D. Occupational history for adults with sickle cell disease compared with healthy siblings. Blood. 2013;122(21):2244.","journal-title":"Blood"},{"issue":"11","key":"14847_CR18","doi-asserted-by":"publisher","first-page":"e1915374","DOI":"10.1001\/jamanetworkopen.2019.15374","volume":"2","author":"D Lubeck","year":"2019","unstructured":"Lubeck D, Agodoa I, Bhakta N, Danese M, Pappu K, Howard R, et al. Estimated life expectancy and income of patients with sickle cell disease compared with those without sickle cell disease. JAMA Netw Open. 2019;2(11):e1915374. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.15374.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"14847_CR19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1182\/bloodadvances.2021006281","volume":"7","author":"KM Johnson","year":"2023","unstructured":"Johnson KM, Jiao B, Ramsey SD, Bender MA, Devine B, Basu A. Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance. Blood Adv. 2023;7(3):365\u201374. https:\/\/doi.org\/10.1182\/bloodadvances.2021006281.","journal-title":"Blood Adv"},{"issue":"6","key":"14847_CR20","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/ajh.21408","volume":"84","author":"TL Kauf","year":"2009","unstructured":"Kauf TL, Coates TD, Huazhi L, Mody-Patel N, Hartzema AG. The cost of health care for children and adults with sickle cell disease. Am J Hematol. 2009;84(6):323\u20137. https:\/\/doi.org\/10.1002\/ajh.21408.","journal-title":"Am J Hematol"},{"issue":"7","key":"14847_CR21","doi-asserted-by":"publisher","first-page":"e0253986","DOI":"10.1371\/journal.pone.0253986","volume":"16","author":"H Leleu","year":"2021","unstructured":"Leleu H, Arlet JB, Habibi A, Etienne-Julan M, Khellaf M, Adjibi Y, et al. Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database. PLoS ONE. 2021;16(7):e0253986. https:\/\/doi.org\/10.1371\/journal.pone.0253986.","journal-title":"PLoS ONE"},{"issue":"4","key":"14847_CR22","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1002\/jha2.575","volume":"3","author":"D Manwani","year":"2022","unstructured":"Manwani D, Burnett AL, Paulose J, Yen GP, Burton T, Anderson A, et al. Treatment patterns and burden of complications associated with sickle cell disease: A US retrospective claims analysis. EJHaem. 2022;3(4):1135\u201344. https:\/\/doi.org\/10.1002\/jha2.575.","journal-title":"EJHaem"},{"key":"14847_CR23","doi-asserted-by":"crossref","unstructured":"Barcelos GT, Besser M, Davidson JA, Filonenko A, Telfer P, Carvalho SJ, et al. Direct healthcare costs associated with sickle cell disease complications: a retrospective cohort study using routinely collected healthcare data in England. BMJ Open. 2025 Dec 23.","DOI":"10.1136\/bmjopen-2025-106082"},{"issue":"5","key":"14847_CR24","doi-asserted-by":"publisher","first-page":"e2314070","DOI":"10.1001\/jamanetworkopen.2023.14070","volume":"6","author":"KM Harris","year":"2023","unstructured":"Harris KM, Preiss L, Varughese T, Bauer A, Calhoun CL, Treadwell M, et al. Examining mental health, education, employment, and pain in sickle cell disease. JAMA Netw Open. 2023;6(5):e2314070. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.14070.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"14847_CR25","first-page":"1053","volume":"35","author":"IE Bultink","year":"2008","unstructured":"Bultink IE, Turkstra F, Dijkmans BA, Voskuyl AE. High prevalence of unemployment in patients with systemic lupus erythematosus: association with organ damage and health-related quality of life. J Rheumatol. 2008;35(6):1053\u20137.","journal-title":"J Rheumatol"},{"issue":"12","key":"14847_CR26","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1002\/art.24063","volume":"59","author":"P Panopalis","year":"2008","unstructured":"Panopalis P, Yazdany J, Gillis JZ, Julian L, Trupin L, Hersh AO, et al. Health care costs and costs associated with changes in work productivity among persons with systemic lupus erythematosus. Arthritis Rheum. 2008;59(12):1788\u201395. https:\/\/doi.org\/10.1002\/art.24063.","journal-title":"Arthritis Rheum"},{"issue":"2","key":"14847_CR27","doi-asserted-by":"publisher","first-page":"205521732210906","DOI":"10.1177\/20552173221090653","volume":"8","author":"D Ellenberger","year":"2022","unstructured":"Ellenberger D, Parciak T, Brola W, Hillert J, Middleton R, Stahmann A, et al. Comparison of employment among people with Multiple Sclerosis across Europe. Mult Scler J Exp Transl Clin. 2022;8(2):20552173221090653. https:\/\/doi.org\/10.1177\/20552173221090653.","journal-title":"Mult Scler J Exp Transl Clin"},{"issue":"8","key":"14847_CR28","doi-asserted-by":"publisher","first-page":"e73322","DOI":"10.1371\/journal.pone.0073322","volume":"8","author":"DC Taylor-Robinson","year":"2013","unstructured":"Taylor-Robinson DC, Smyth R, Diggle PJ, Whitehead M. A longitudinal study of the impact of social deprivation and disease severity on employment status in the UK cystic fibrosis population. PLoS ONE. 2013;8(8):e73322. https:\/\/doi.org\/10.1371\/journal.pone.0073322.","journal-title":"PLoS ONE"},{"key":"14847_CR29","unstructured":"CPRD. Clinical practice research datalink. 2024. Available from: https:\/\/www.cprd.com\/."},{"key":"14847_CR30","doi-asserted-by":"publisher","unstructured":"CPRD. Clinical practice research datalink. Aurum March 2025 (Version 2025.03.001). 2025. Available from: https:\/\/doi.org\/10.48329\/6570-ge08.","DOI":"10.48329\/6570-ge08"},{"key":"14847_CR31","unstructured":"HES. Hospital Episode Statistics. A curated data product containing details about admissions, outpatient appointments and historical accident and emergency attendances at NHS hospitals in England. 2024. Available from: https:\/\/digital.nhs.uk\/data-and-information\/data-tools-and-services\/data-services\/hospital-episode-statistics."},{"key":"14847_CR32","unstructured":"National Institute for Health and Care Research. CPRD linked data. 2025. Available from: https:\/\/www.cprd.com\/cprd-linked-data#Death%20Registration%20data."},{"issue":"6","key":"14847_CR33","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1093\/ije\/dyz034","volume":"48","author":"A Wolf","year":"2019","unstructured":"Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J, Myles P. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol. 2019;48(6):1740\u2013g. https:\/\/doi.org\/10.1093\/ije\/dyz034.","journal-title":"Int J Epidemiol"},{"key":"14847_CR34","unstructured":"NHS Classifications Brower. OPCS-4.10. Available from: https:\/\/classbrowser.nhs.uk\/#\/book\/OPCS-4.10."},{"key":"14847_CR35","unstructured":"Office for National Statistics. Earnings and hours worked, age group: ASHE Table 6.6a 2021 revised edition of this dataset. 2021. Available from: https:\/\/www.ons.gov.uk\/employmentandlabourmarket\/peopleinwork\/earningsandworkinghours\/datasets\/agegroupashetable6."},{"key":"14847_CR36","unstructured":"Office for National Statistics. Average actual weekly hours of work for full-time workers (seasonally adjusted). 2025. Available from: https:\/\/www.ons.gov.uk\/employmentandlabourmarket\/peopleinwork\/earningsandworkinghours\/timeseries\/ybuy\/lms."},{"key":"14847_CR37","volume-title":"Evaluation of Health Services","author":"H-J Choi","year":"2019","unstructured":"Choi HJ, Lee EW. Methodology of estimating socioeconomic burden of disease using National Health Insurance (NHI) data. In: Sandeep R, Aida Isabel T, editors. Evaluation of Health Services. Rijeka: IntechOpen; 2019."},{"key":"14847_CR38","unstructured":"Office for National Statistics. Earnings and hours worked, age group: ASHE Table 6 [2021 revised edition]. Available from: https:\/\/www.ons.gov.uk\/file?uri=\/employmentandlabourmarket\/peopleinwork\/earningsandworkinghours\/datasets\/agegroupashetable6\/2021revised\/ashetable62021revised.zip."},{"key":"14847_CR39","unstructured":"Office for National Statistics. Consumer price inflation, UK: December 2021 updated January 19, 2022. Available from: https:\/\/www.ons.gov.uk\/economy\/inflationandpriceindices\/bulletins\/consumerpriceinflation\/december2021."},{"key":"14847_CR40","unstructured":"Treasury HM. The green book and accompanying guidance. 2020. updated October 15. 2025. Available from: https:\/\/www.gov.uk\/government\/collections\/the-green-book-and-accompanying-guidance-and-documents."},{"issue":"23","key":"14847_CR41","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1182\/blood.V126.23.71.71","volume":"126","author":"K Gardner","year":"2015","unstructured":"Gardner K, Douiri A, Allman M, Drasar E, Awogbade M, Thein SL. Survival in sickle cell disease: Data from a well-resourced, national health system setting. Blood. 2015;126(23):71. https:\/\/doi.org\/10.1182\/blood.V126.23.71.71.","journal-title":"Blood"},{"key":"14847_CR42","unstructured":"Office for National Statistics. Figure 1: Average weekly earnings for both total and regular pay showed a steady increase over the long term. Available from: https:\/\/www.ons.gov.uk\/generator?uri=\/employmentandlabourmarket\/peopleinwork\/employmentandemployeetypes\/bulletins\/averageweeklyearningsingreatbritain\/october2024\/9be90b68&format=xls."},{"issue":"1","key":"14847_CR43","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1365-2125.2009.03537.x","volume":"69","author":"E Herrett","year":"2010","unstructured":"Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ. Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol. 2010;69(1):4\u201314. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03537.x.","journal-title":"Br J Clin Pharmacol"},{"key":"14847_CR44","unstructured":"National Health Service. National haemoglobinopathy registry annual report 2018\/19."},{"key":"14847_CR45","unstructured":"National Health Service. National haemoglobinopathy registry annual report 2023\/2024."},{"key":"14847_CR46","doi-asserted-by":"publisher","first-page":"102567","DOI":"10.1016\/j.bcmd.2021.102567","volume":"89","author":"FB Piel","year":"2021","unstructured":"Piel FB, Jobanputra M, Gallagher M, Weber J, Laird SG, McGahan M. Co-morbidities and mortality in patients with sickle cell disease in England: A 10-year cohort analysis using hospital episodes statistics (HES) data. Blood Cells Mol Dis. 2021;89:102567. https:\/\/doi.org\/10.1016\/j.bcmd.2021.102567.","journal-title":"Blood Cells Mol Dis"},{"key":"14847_CR47","doi-asserted-by":"publisher","first-page":"1205941","DOI":"10.3389\/frhem.2023.1205941","volume":"2","author":"C Kjellander","year":"2023","unstructured":"Kjellander C, Hernlund E, Iverg\u00e5rd M, Svedbom A, Dibbern T, Stenling A, et al. Economic burden of sickle cell disease in Sweden: a population-based national register study with 13 years follow up. Front Hematol. 2023;2:1205941. https:\/\/doi.org\/10.3389\/frhem.2023.1205941.","journal-title":"Front Hematol"},{"issue":"14","key":"14847_CR48","doi-asserted-by":"publisher","first-page":"3629","DOI":"10.1182\/bloodadvances.2023012477","volume":"8","author":"S Lanzkron","year":"2024","unstructured":"Lanzkron S, Crook N, Wu J, Hussain S, Curtis RG, Robertson D, et al. Costs and impact of disease in adults with sickle cell disease: a pilot study. Blood Adv. 2024;8(14):3629\u201338. https:\/\/doi.org\/10.1182\/bloodadvances.2023012477.","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"14847_CR49","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1182\/blood-2023-187822","volume":"142","author":"J Kanter","year":"2023","unstructured":"Kanter J, Lanzkron S, Saif Ur Rehman S, Little JA, Ullman MM, Curtis R, et al. Association of health-related quality of life and work productivity with clinical characteristics in adults with sickle cell disease. Blood. 2023;142(Supplement 1):2377. https:\/\/doi.org\/10.1182\/blood-2023-187822.","journal-title":"Blood"},{"issue":"1","key":"14847_CR50","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s41687-024-00784-y","volume":"8","author":"M Besser","year":"2024","unstructured":"Besser M, O\u2019Sullivan SB, Bourke S, Longworth L, Barcelos GT, Oluboyede Y. Economic burden and quality of life of caregivers of patients with sickle cell disease in the United Kingdom and France: a cross-sectional study. J Patient Rep Outcomes. 2024;8(1):110. https:\/\/doi.org\/10.1186\/s41687-024-00784-y.","journal-title":"J Patient Rep Outcomes"},{"issue":"9","key":"14847_CR51","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.18553\/jmcp.2020.20009","volume":"26","author":"A Campbell","year":"2020","unstructured":"Campbell A, Cong Z, Agodoa I, Song X, Martinez DJ, Black D, et al. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study. J Manag Care Spec Pharm. 2020;26(9):1121\u20139. https:\/\/doi.org\/10.18553\/jmcp.2020.20009.","journal-title":"J Manag Care Spec Pharm"},{"key":"14847_CR52","unstructured":"Federal Reserve Bank of St. Louis. Estimate of median household income for San Francisco County\/City, CA. updated February 9, 2026. Available from: https:\/\/fred.stlouisfed.org\/series\/MHICA06075A052NCEN?utm."},{"issue":"8","key":"14847_CR53","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s10198-022-01547-6","volume":"24","author":"C Murley","year":"2023","unstructured":"Murley C, Tinghog P, Teni FS, Machado A, Alexanderson K, Hillert J, et al. Excess costs of multiple sclerosis: a register-based study in Sweden. Eur J Health Econ. 2023;24(8):1357\u201371. https:\/\/doi.org\/10.1007\/s10198-022-01547-6.","journal-title":"Eur J Health Econ"},{"key":"14847_CR54","unstructured":"Statistics Sweden. Average monthly salary and salary dispersion in SEK in the regions by occupation and sex. Year 2014\u20132024. Available from: https:\/\/www.statistikdatabasen.scb.se\/pxweb\/en\/ssd\/START__AM__AM0105__AM0105A\/Landsting2g12\/."},{"key":"14847_CR55","unstructured":"Eurostat. GDP per capita in PPS. updated March 25, 2026. Available from: https:\/\/ec.europa.eu\/eurostat\/databrowser\/view\/tec00114\/default\/table?lang=en&utm."},{"key":"14847_CR56","unstructured":"Office for National Statistics. Birth characteristics in England and Wales: 2020. updated January 13, 2022. Available from: https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/birthsdeathsandmarriages\/livebirths\/bulletins\/birthcharacteristicsinenglandandwales\/2020."},{"key":"14847_CR57","unstructured":"National Haemoglobinopathy Registry. Annual reports. Available from: https:\/\/nhr.mdsas.com\/index.php\/publications\/."},{"key":"14847_CR58","unstructured":"Organisation for Economic Co-operation and Development. Purchasing power parities (PPP). 2023. Available from: https:\/\/www.oecd.org\/en\/data\/indicators\/purchasing-power-parities-ppp.html?oecdcontrol-00b22b2429-var3=2019&oecdcontrol-38c744bfa4-var1=OAVG%7COECD%7CGBR%7CUSA."},{"key":"14847_CR59","unstructured":"GOV.UK. Guidance: public funds. 2025. Available from: https:\/\/www.gov.uk\/government\/publications\/public-funds--2\/public-funds."}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-026-14847-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14847-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-026-14847-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:59:11Z","timestamp":1786406351000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12913-026-14847-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["14847"],"URL":"https:\/\/doi.org\/10.1186\/s12913-026-14847-x","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"13 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study adhered to the Declaration of Helsinki. Patient data were obtained under licence from the UK Medicines and Healthcare products Regulatory Agency following study protocol approval by the CPRD Independent Scientific Advisory Committee (Study Protocol Number: 21_000422). CPRD has ethics approval from the Health Research Authority to support research using anonymised patient data. As patients cannot be identified from the data, individual patient consent is not required however, CPRD complies with national-level policies that allow patients to opt out of data from their health records being used for research, such as the National Data Opt-Out policy and the Type 1 opt-out scheme. For more information see\n                      \n                      .","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Martin Besser reports advisory boards from Agios, Pfizer, GBT, Novartis, Terumo, Prime Global, Sanofi as well as speakers\u2019 honoraria from Pfizer, Terumo. Caoimhe T Rice and Jennifer A Davidson are employees of PPD\u2122 Evidera\u2122 Real-World Data & Scientific Solutions, part of Thermo Fisher Scientific which received financial support from Pfizer to conduct this research. Jeremy Brown was previously employed by CorEvitas, part of Thermo Fisher Scientific. Christine L Baker, Carmine Colavecchia, and Giovanna T Barcelos are employed by Pfizer, and equity owners.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1091"}}